RxDoctor Payments Data

Emad Barsoum, MD

Interventional Cardiology · Plainfield, NJNPI 1922313907

Payments from drug & device makers

$8,030in general payments, 2019–2025

Across 178 payments — averaging $45.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$2K
  • Abbott$2K
  • Boston Scientific$1K
  • AstraZeneca$451
  • Shockwave Medical, Inc$432
  • Medtronic$279
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$6088%
  • Food & beverage$7,40992%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,030 in reported general payments places this provider in the 40th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$282,682
Medicare patients
548
Services billed
2,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$57,767
BrilintaTicagrelor23$21,096
Atorvastatin Calcium137$1,459
Metoprolol Succinate94$988
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$897
Losartan Potassium98$735
Carvedilol74$734
ClopidogrelClopidogrel Bisulfate69$669
Amlodipine Besylate77$495
Midodrine Hcl12$425
Metoprolol Tartrate51$371
Hydralazine Hcl17$361
Valsartan13$230
Rosuvastatin Calcium18$177
Furosemide30$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$57,76762 claims
AstraZenecaBrilinta$451$21,09623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Plainfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →